Riskpilot← Back to searchSign inGet full accessBiofarma Holding A/S
A/SActiveCVR 42243795Naverland 22Activities of holding companies · NACE 6421Est. 2021— employees
Revenue 2024
—
EBITDA margin
—
Equity ratio
99.5%
Financial strength
Net profit 2024
DKK 9,9M
+100% vs 2023
| Revenue | — | — |
| EBITDA | DKK -221K | — |
| Net profit | DKK 9,9M | +100% |
| Total assets | DKK 94,1M | +12% |
| Equity | DKK 93,7M | +12% |
| Employees | — | — |
Legal name
Biofarma Holding A/S
CVR number
42243795
Legal form
Aktieselskab
NACE code
6421 · Activities of holding companies
Founded
23. marts 2021
Share capital
DKK 500.000
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden i forening med et bestyrelsesmedlem eller en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive handel, investeringer og holdingvirksomhed, herunder, så længe bestyrelsen finder det rigtigt, helt eller delvist at eje aktiekapitalen i Biofarma Logistik A/S og om fornødent yde støtte til driften af denne virksomhed.
Address
Naverland 22
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | — |
| Staff expenses | -0 | -0 | -0 | -0 |
| EBITDA | -145 | -238 | 0 | -221 |
| Depreciation & amort. | -0 | -0 | -0 | -0 |
| EBIT | -145 | -238 | 0 | -221 |
| Net financials | -1.326 | -1.197 | 4.940 | 11.487 |
| Profit before tax | 2.774 | -1.435 | 4.940 | 11.266 |
| Tax | 206 | -920 | 1 | 1.374 |
| Net profit | 2.568 | -515 | 4.939 | 9.891 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 78.378 | 78.292 | 84.179 | 94.098 |
| Equity | 78.068 | 77.552 | 83.770 | 93.661 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 310 | 739 | 409 | 436 |
| Total debt | 310 | 739 | 409 | 436 |
EBITDA margin
-22104400.0%
This company
15.8%
Market median
-139901366% vs market
20212024
Equity ratio
99.5%
This company
38.2%
Market median
+160% vs market
20212024
Return on equity
10.6%
This company
18.4%
Market median
+42% vs market
20212024
Net profit margin
989148500.0%
This company
8.1%
Market median
+12211709777% vs market
20212024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20212024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-03-23 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SW Management | Management | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2021 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
CAND.PHARM. POVL M. ASSENS FOND | Company | 100.0% | 100.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CAND.PHARM. POVL M. ASSENS FOND
Biofarma Holding A/S Board members of Biofarma Holding A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Søren Wang Petersen | Management | 0 companies |
| Tyge Jesper Rothe | Chairman | 0 companies |
| Niels Christian Assens | Board of Directors | 0 companies |